Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of usefulness of manual reduction in the management of adult acute irreducible abdominal wall hernia: a study from a community-based teaching hospital.

Hernia : the journal of hernias and abdominal wall surgery·2026

Same author

Analysis of <i>PIK3CA</i> mutations in the lysate of sentinel lymph nodes in patients with early breast cancer.

Frontiers in oncology·2026

Same author

A rare case of mastitis involving granulomatosis with polyangiitis after immune checkpoint inhibitor therapy.

International cancer conference journal·2026

Same author

Roles and Therapeutic Application of Vasohibin-2 in Cancers.

The Tohoku journal of experimental medicine·2026

Same author

[A Case Study of Severe Myelosuppression Induced by Adjuvant Chemotherapy in a Breast Cancer Patient with Concurrent Immune Thrombocytopenia(ITP)].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Same author

[Treatment Outcomes for Six Cases of Gastric Cancer with Brain Metastases].

Gan to kagaku ryoho. Cancer & chemotherapy·2026

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Rat Mesentery Angiogenesis Assay

Rat Mesentery Angiogenesis Assay

Published on: June 18, 2011

[Anti-angiogenic drugs].

Yasufumi Sato¹

¹Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku University.

Nihon Rinsho. Japanese Journal of Clinical Medicine

|June 12, 2010

Summary

Anti-angiogenic therapies, like bevacizumab, target new blood vessel formation crucial for tumor growth. These treatments represent a significant advancement in cancer therapy, offering new strategies for controlling tumor progression and metastasis.

Area of Science:

Oncology
Vascular Biology

Background:

Angiogenesis, or the formation of new blood vessels, is essential for tumor growth and metastasis.
Dysregulated angiogenesis is a hallmark of cancer, making it a critical therapeutic target.

Purpose of the Study:

This review focuses on the current status of anti-angiogenic treatments in cancer therapy.
To highlight the clinical significance and advancements in targeting tumor-induced angiogenesis.

Main Methods:

Review of literature on angiogenesis inhibitors in cancer treatment.
Analysis of the development and clinical application of anti-VEGF therapies.

Main Results:

Bevacizumab, an anti-VEGF antibody, established the clinical efficacy of anti-angiogenic drugs in cancer.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Preparing a ⁶⁸Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 12, 2026

Rat Mesentery Angiogenesis Assay

Rat Mesentery Angiogenesis Assay

Published on: June 18, 2011

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Preparing a ⁶⁸Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

Multiple drugs targeting VEGF-mediated pathways have been developed and utilized in clinical settings.

Anti-angiogenic drugs are now a recognized cornerstone in the management of various cancers.

Conclusions:

Targeting angiogenesis is a validated and effective strategy for cancer treatment.
The development of anti-angiogenic therapies has significantly advanced cancer care.
Continued research into novel anti-angiogenic agents holds promise for future cancer therapies.